{"protocolSection":{"identificationModule":{"nctId":"NCT01455935","orgStudyIdInfo":{"id":"NEU 3200411A"},"organization":{"fullName":"Jacobs Neurological Institute","class":"OTHER"},"briefTitle":"Wake up Symptomatic Stroke - Benefit of Intravenous Clot Busters or Endovascular Intervention","officialTitle":"Wake up Symptomatic Stroke in Acute Brain Ischemia (WASSABI) Trial","acronym":"WASSABI"},"statusModule":{"statusVerifiedDate":"2012-03","overallStatus":"UNKNOWN","lastKnownStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2011-11"},"primaryCompletionDateStruct":{"date":"2013-12","type":"ESTIMATED"},"completionDateStruct":{"date":"2014-02","type":"ESTIMATED"},"studyFirstSubmitDate":"2011-10-07","studyFirstSubmitQcDate":"2011-10-18","studyFirstPostDateStruct":{"date":"2011-10-20","type":"ESTIMATED"},"lastUpdateSubmitDate":"2012-03-29","lastUpdatePostDateStruct":{"date":"2012-03-30","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Tareq Kass-Hout","investigatorTitle":"Chief Vascular/Neurology Resident in charge of stroke","investigatorAffiliation":"Jacobs Neurological Institute"},"leadSponsor":{"name":"Jacobs Neurological Institute","class":"OTHER"},"collaborators":[{"name":"University at Buffalo Neurosurgery","class":"OTHER"},{"name":"Genentech, Inc.","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The purpose of the trial is to study the safety and the effectiveness of using CT Perfusion studies as an indicator to treat stroke patients with unknown time of onset."},"conditionsModule":{"conditions":["Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"FACTORIAL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","whoMasked":["OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":90,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Medical Therapy","type":"ACTIVE_COMPARATOR","description":"Current standard of care per the latest stroke guidelines\n\n* Permissive Hypertension up to 220\n* Antipletelets therapy:\n\n  1. ASA 81 mg PO daily or\n  2. Plavix 75 mg PO daily or\n  3. Aggrenox 225mg PO twice daily\n* Anti-inflammatory therapy:\n\n  1. Lipitor 80 mg PO daily or\n  2. Crestor 20 mg PO daily","interventionNames":["Drug: Anti-platelets and statin"]},{"label":"Intravenous Thrombolysis","type":"EXPERIMENTAL","description":"Full dose Intravenous thrombolysis\n\n* 0.9 mg/kg\n* Maximum dose is 90 mg\n* 10% of the dose will be given over one minute\n* 90% of the dose will be infused over 1 hour\n* Admission to Neuro Intensive Care Unit(NICU) for 24 hours if no complications\n* Neuro checks every 5 minutes during the infusion\n* Neuro checks every hour after the infusion for 24 hours","interventionNames":["Drug: alteplase"]},{"label":"Intra-Arterial Therapy","type":"EXPERIMENTAL","description":"-Choice of therapy per experienced Endovascular surgeon and includes:\n\n1. Intra arterial Activase (Maximum dose of 22 mg)\n2. MERCI device (Maximum of 3 tries per device, no standard time frame for how long the procedure takes)\n3. PENUMBRA device (no standard time frame for how long the procedure takes)","interventionNames":["Procedure: intra arterial intervention"]}],"interventions":[{"type":"DRUG","name":"Anti-platelets and statin","armGroupLabels":["Medical Therapy"]},{"type":"DRUG","name":"alteplase","description":"Full dose Intravenous thrombolysis\n\n* 0.9 mg/kg\n* Maximum dose is 90 mg\n* 10% of the dose will be given over one minute\n* 90% of the dose will be infused over 1 hour\n* Admission to Neuro Intensive Care Unit(NICU) for 24 hours if no complications\n* Neuro checks every 5 minutes during the infusion\n* Neuro checks every hour after the infusion for 24 hours","armGroupLabels":["Intravenous Thrombolysis"]},{"type":"PROCEDURE","name":"intra arterial intervention","description":"1. Intra arterial Activase (Maximum dose of 22 mg)\n2. MERCI device (Maximum of 3 tries per device, no standard time frame for how long the procedure takes)\n3. PENUMBRA device (no standard time frame for how long the procedure takes)","armGroupLabels":["Intra-Arterial Therapy"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Modified Rankin Scale (mRS)","description":"Modified Rankin Scale (mRS) 90 days post treatment","timeFrame":"90 days"}],"secondaryOutcomes":[{"measure":"National Institute of Health Stroke Scale (NIHSS)","description":"National Institute of Health Stroke Scale (NIHSS) 24 hours post treatment.","timeFrame":"24 hour"},{"measure":"National Institute of Health Stroke Scale (NIHSS)","description":"National Institute of Health Stroke Scale (NIHSS) at discharge (3-29 days)","timeFrame":"3-29 day"},{"measure":"Modified Rankin Scale (mRS)","description":"Modified Rankin Scale (mRS) at 30 days post treatment","timeFrame":"30 post treatment"},{"measure":"Thrombolysis In Myocardial Infarction (TIMI) Flow","description":"Thrombolysis In Myocardial Infarction (TIMI) flow pre and post the intervention as an indicator of revascularization rate","timeFrame":"Pre - up to1 hour prior to procedure and post will be up to1 hour after completion of procedure"},{"measure":"Thomboylsis in Cerebral Ischemia (TICI) flow","description":"Thomboylsis in Cerebral Ischemia (TICI) flow pre and post intervention as an indicator of revascularization rate","timeFrame":"Pre - will be no more than 1 hour prior to procedure and post will be no more then 1 hour after completion of procedure"},{"measure":"symptomatic intracranial Hemorrhage (ICH)","description":"Incidence of symptomatic symptomatic intracranial Hemorrhage (ICH) within 72 hours of intervention defined by ECASSIII as 4 points worsening in NIHSS","timeFrame":"72 hours"},{"measure":"National Institute of Health Stroke Scale (NIHSS)","description":"at 30 Day visit National Institute of Health Stroke Scale (NIHSS) will be assessed","timeFrame":"30 Days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nInclusion Criteria: To be eligible for entry into this study, candidates must meet all of the following eligibility criteria at the time of Emergency Department presentation:\n\n1. Age: 18-80 years old\n2. Ischemic Wake Up Stroke (Unknown time of onset but less than 24 hours since last seen normal)\n3. National Institute of Health Stroke Scale (NIHSS) 8-22\n4. Evidence of penumbra on Computed Tomography Perfusion(CTP) as mentioned above\n5. Alberta Stroke Program Early Computed Tomography (CT) Score (ASPECTS 7 or more)\n6. Signed informed consent\n\nExclusion Criteria:\n\nExclusion Criteria: Potential study patients will be excluded from study entry if any of the following exclusion criteria exist at the time of screening:\n\n1. Evidence of intracranial hemorrhage (Intracerebral hematoma, intraventricular hemorrhage, subarachnoid hemorrhage (SAH), epidural hemorrhage, acute or chronic subdural hematoma (SDH)) on the baseline CT\n2. Historical Modified Rankin Scale (mRS) of â‰¥2\n3. National Institute of Health Stroke Scale (NIHSS)\\<8 at the time of treatment\n4. Positive pregnancy test in women at age of childbearing\n5. Intracranial or intraspinal surgery within 3 months\n6. Stroke or serious head injury within 3 months\n7. History of intracranial hemorrhage\n8. Uncontrolled hypertension at time of treatment (eg, \\>185 mm Hg systolic or \\>110 mm Hg diastolic)\n9. Seizure at the onset of stroke\n10. Active internal bleeding\n11. Intracranial neoplasm\n12. Arteriovenous malformation or aneurysm\n13. Clinical presentation suggesting post-MI pericarditis\n14. Known bleeding diathesis including but not limited to current use of oral anticoagulants producing an Internation normalized ratio (INR) \\>1.7\n15. Internation normalized ratio (INR) \\>1.7\n16. Administration of heparin within 48 hours preceding the onset of stroke with an elevated activated Partial Thromboplastin Time(aPTT) at presentation\n17. Platelet count \\<100,000/mm\n18. Major surgery within 2 weeks\n19. GastroIntestinal (GI) or urinary tract hemorrhage within 3 weeks\n20. Aggressive treatment required to lower blood pressure\n21. Glucose level \\<50 or \\>400 mg/dL\n22. Arterial puncture at a noncompressible site or lumbar puncture within 1 week","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Tareq Kass-Hout, MD","role":"CONTACT","phone":"716-887-5548","email":"kasshouttareq@gmail.com"}],"overallOfficials":[{"name":"Elad I Levy, MD","affiliation":"University at Buffalo Neurosurgery","role":"STUDY_DIRECTOR"},{"name":"Tareq Kass-Hout, MD","affiliation":"Jacobs Neurological Institute","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Millard Fillmore Gates Circle Hospital","status":"RECRUITING","city":"Buffalo","state":"New York","zip":"14209","country":"United States","contacts":[{"name":"Annemarie Crumlish","role":"CONTACT","phone":"716-887-5548","email":"acrumlish@thejni.org"},{"name":"Tareq Kass-Hout, MD","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Elad Levy, MD","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Adnan H Siddiqui, MD,PhD","role":"SUB_INVESTIGATOR"},{"name":"Kenneth V Snyder, MD, PhD","role":"SUB_INVESTIGATOR"},{"name":"L N Hopkins, MD","role":"SUB_INVESTIGATOR"},{"name":"Robert N Sawyer, MD","role":"SUB_INVESTIGATOR"},{"name":"Marilou Ching, MD","role":"SUB_INVESTIGATOR"},{"name":"David Janicke, MD","role":"SUB_INVESTIGATOR"}],"geoPoint":{"lat":42.88645,"lon":-78.87837}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000010959","term":"Tissue Plasminogen Activator"}],"ancestors":[{"id":"D000005343","term":"Fibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"}],"browseLeaves":[{"id":"M351","name":"Atorvastatin","relevance":"LOW"},{"id":"M298","name":"Rosuvastatin Calcium","relevance":"LOW"},{"id":"M1669","name":"Clopidogrel","relevance":"LOW"},{"id":"M13539","name":"Tissue Plasminogen Activator","asFound":"Patient Reported Outcomes","relevance":"HIGH"},{"id":"M3907","name":"Anti-Inflammatory Agents","relevance":"LOW"},{"id":"M20845","name":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","relevance":"LOW"},{"id":"M256","name":"Aspirin, Dipyridamole Drug Combination","relevance":"LOW"},{"id":"M13538","name":"Plasminogen","relevance":"LOW"},{"id":"M8163","name":"Fibrinolytic Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"Lipd","name":"Lipid Regulating Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"},{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"Infl","name":"Anti-Inflammatory Agents"}]}},"hasResults":false}